Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of EA1080 in Healthy Male Volunteers
NCT04223960Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EA1080 in inflammatory bowel disease (IBD) (2 arms), sponsored by EA Pharma Co., Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events, Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Parameter Values and 2 more. Started Jan 2020; status: completed.
02
Drugs
EA1080
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT04223960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223960.